The role of iron in brain ageing and neurodegenerative disorders, Lancet Neurol, vol.13, pp.1045-60, 2014. ,
Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics, J Neurochem, vol.139, pp.179-197, 2016. ,
Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice, which low dopaminergic iron status was associated with development of Parkinsons in a mouse model, vol.113, pp.3428-3435, 2016. ,
DOI : 10.1073/pnas.1519473113
URL : http://europepmc.org/articles/pmc4822577?pdf=render
Iron and dopamine: a toxic couple, Brain, vol.139, pp.1026-1061, 2016. ,
DOI : 10.1093/brain/aww022
URL : https://academic.oup.com/brain/article-pdf/139/4/1026/7461989/aww022.pdf
,
Changing iron content of the mouse brain during development, Metallomics, vol.4, pp.761-70, 2012. ,
Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1, Nature, vol.468, pp.696-700, 2010. ,
,
, Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease, Ann Neurol, vol.73, pp.554-559, 2013.
Parkinson's disease iron deposition caused by nitric oxideinduced loss of ?-amyloid precursor protein, J Neurosci, vol.35, pp.3591-3598, 2015. ,
Targeting chelatable iron as a therapeutic modality in Parkinson's disease, Antioxid Redox Signal, vol.21, pp.195-210, 2014. ,
,
, Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse, Neurobiol Dis, vol.81, pp.168-75, 2015.
Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up, PLoS One, vol.8, p.57904, 2013. ,
Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?, PLoS One, vol.11, p.147947, 2016. ,
Meta-analysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements, Sci Rep, vol.6, p.36669, 2016. ,
Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease. Mov Disord, 2017. ,
Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease, Parkinsonism Relat Disord, vol.19, pp.1136-1142, 2013. ,
,
The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease, Brain, vol.140, pp.118-131, 2017. ,
,
Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care, J Magn Reson Imaging, 2017. ,
In vivo detection of lateral-ventral tier nigral degeneration in Parkinson's disease. Hum Brain Mapp, 2017. ,
Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury, Arch Neurol, vol.59, pp.999-1005, 2002. ,
,
In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage, Mov Disord, vol.20, pp.1278-85, 2005. ,
Tau deficiency induces parkinsonism with dementia by impairing APPmediated iron export, Nat Med, vol.18, pp.291-295, 2012. ,
Functional relevance of ceruloplasmin mutations in Parkinson's disease, FASEB J, vol.19, pp.1851-1854, 2005. ,
The critical role of Nramp1 in degrading ?-synuclein oligomers in microglia under iron overload condition, Neurobiol Dis, vol.104, pp.61-72, 2017. ,
Pooled analysis of iron-related genes in ,
URL : https://hal.archives-ouvertes.fr/inserm-01160048
, Parkinson's disease: association with transferrin, Neurobiol Dis, vol.62, pp.172-180, 2014.
Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease, Proc Natl Acad Sci U S A, vol.92, pp.9603-9610, 1995. ,
,
, Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease, Proc Natl Acad Sci U S A, vol.105, pp.18578-83, 2008.
Post translational changes to ?-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease, Mol Neurodegener, vol.12, p.45, 2017. ,
Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice, ACS Chem Neurosci, vol.7, pp.119-148, 2016. ,
Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of AlphaSynuclein Aggregation, 2017. ,
Ferroptosis: an irondependent form of nonapoptotic cell death, Cell, vol.149, pp.1060-72, 2012. ,
,
Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice, Nat Cell Biol, vol.16, pp.1180-91, 2014. ,
,
Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC, Neurobiol Dis, vol.94, pp.169-178, 2016. ,
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators, Free Radic Biol Med, vol.62, pp.52-64, 2013. ,
Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators, Metallomics, vol.7, pp.867-76, 2015. ,
Regional siderosis: a new challenge for iron chelation therapy, Front Pharmacol, vol.4, p.167, 2013. ,
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease, Sci Rep, vol.7, p.1398, 2017. ,
, Australian Imaging Biomarkers and Lifestyle